Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study of VYD2311 for the Prevention of COVID-19
NCT07298434 · View on ClinicalTrials.gov ↗
Study Summary
The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adults and adolescents at least 12 years old. Participants in this study will be given a "study drug" that will be either VYD2311 or placebo. The study drug will be given as a shot into the muscle in the participant's upper thigh or upper arm once a month with a total of 3 shots during the study. This study will help researchers see how well VYD2311 works to prevent COVID-19 during the 90 days after the first shot. The study will also look at the safety and tolerability of VYD2311, how the study drug is processed by the body (pharmacokinetics), how the immune system reacts to the study drug (immunogenicity), and how well VYD2311 can block the virus from infecting cells (neutralization). To do these tests, your blood will be drawn at certain times during the study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VYD2311-SD
- DRUG VYD2311-MD
Study Locations (20)
Texas
- Invivyd Investigative Site — Houston
- Invivyd Investigative Site — Houston-2
- Invivyd Investigative Site — Irving
- Invivyd Investigative Site — Sugar Land
California
- Invivyd Investigative Site — Long Beach
- Inviviyd Investigative Site — San Diego
Florida
- Invivyd Investigative Site — Orlando
Georgia
- Invivyd Investigative Site — Hinesville
Illinois
- Invivyd Investigative Site — Melrose Park
Kansas
- Invivyd Investigative Site — Lenexa
Maryland
- Invivyd Investigative Site — Silver Spring
Massachusetts
- Invivyd Investigative Site — Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,770 participants |
| Start Date | 2026-01-08 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07298434
The ClinicalTrials.gov registry entry for NCT07298434 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,770 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invivyd, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07298434 reports 20 study locations spanning 16 distinct geographic areas — top geographies include Texas, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07298434 about?
NCT07298434 is a clinical study titled "Study of VYD2311 for the Prevention of COVID-19". The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adul...
What is the current status of trial NCT07298434?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,770 participants. The study started on 2026-01-08. Estimated completion is 2026-06.
What conditions does trial NCT07298434 study?
This clinical trial studies the following conditions: COVID-19. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07298434?
The interventions under investigation include: Placebo (DRUG), VYD2311-SD (DRUG), VYD2311-MD (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07298434?
This trial is sponsored by Invivyd, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07298434 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.